Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden

CONCLUSIONS: This partitioned survival analysis suggests that pembrolizumab plus lenvatinib is cost effective compared with chemotherapy in Sweden for women with advanced or recurrent endometrial carcinoma following previous systemic therapy. Results were robust to mismatch repair status and to changes in parameters/assumptions.PMID:38470404 | DOI:10.1080/13696998.2024.2329022

Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Lewis Ralph Kate Young Navneet Upadhyay Vimalanand Shrikant Prabhu Christina Ljungcrantz Rachid Massaad Ruifeng Xu Anna Giertz Adil Merchant Robert Orlowski Linda Duska Source Type: research